Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REGN4659
- Development stage
- Discontinued
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
REGN4659 is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that targets cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), a receptor expressed on T cells. By binding to CTLA4, REGN4659 acts as an immune checkpoint inhibitor, blocking the inhibitory signal mediated by CTLA4 and thereby enhancing T-cell activation and proliferation. This mechanism is intended to promote an anti-tumor immune response with potential antineoplastic activity. The drug was developed primarily for the treatment of cancer, including non-small cell lung cancer[1][2][5][7][9].
- Other names
- anti-CTLA-4 monoclonal antibody REGN4659anti-CTLA4 monoclonal antibody REGN4659anti-CTLA 4 monoclonal antibody REGN4659anti-CTLA-4 monoclonal antibodyanti-CTLA4 monoclonal antibodyanti-CTLA 4 monoclonal antibody
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on REGN4659.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REGN4659.